Skip to main content
Diasorin logo

Diasorin — Investor Relations & Filings

Ticker · DIA ISIN · IT0003492391 LEI · 8156002878BDF0EE4348 XMIL Manufacturing
Open in API
Filings indexed 817 across all filing types
Latest filing 2021-04-28 Capital/Financing Update
Country IT Italy
Listing XMIL DIA

About Diasorin

https://diasoringroup.com/en

Diasorin is a global leader in the In Vitro Diagnostic (IVD) field, developing, producing, and marketing reagent kits for laboratory diagnostics. The company specializes in immunodiagnostics and molecular diagnostics. Its immunodiagnostics technology is based on detecting antibodies and antigens in fluid samples to identify diseases or measure physiological markers. The molecular diagnostics division provides flexible tools using targeted and multiplex technologies to detect pathogens in biological specimens. Since 2021, Diasorin has also been active in the Life Science business, offering platforms for biomedical research, clinical diagnostics, and drug discovery. Through its product lines, such as the LIAISON® family of analyzers and assays, the company aims to empower healthcare providers with actionable information to improve patient care, enable faster triage, and reduce unnecessary antibiotic use.

Recent filings

Filing Released Lang Actions
DiaSorin colloca con successo il prestito obbligazionario senior unsecured equity-linked da euro 500 milioni con scadenza al 2028
Capital/Financing Update Classification · 99% confidence The document is a formal announcement from DiaSorin S.p.A. dated April 28, 2021, regarding the successful placement of a €500 million senior unsecured equity-linked bond maturing in 2028. The subject line explicitly states 'DiaSorin colloca con successo il prestito obbligazionario senior unsecured equity linked da euro 500 milioni con scadenza al 2028'. This clearly indicates a financing activity involving the issuance of debt instruments (bonds). This aligns directly with the definition of 'Capital/Financing Update' (CAP), which covers company fundraising and financing activities.
2021-04-28 Italian
DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028
Capital/Financing Update Classification · 99% confidence The document is an official notice from DiaSorin S.p.A. dated April 28, 2021, titled "DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028". It details the successful pricing of a bond offering, the use of proceeds (to finance the acquisition of Luminex), conversion price, settlement date, and includes extensive legal disclaimers regarding distribution in various jurisdictions (US, Canada, EEA, UK). This clearly describes a significant financing activity, specifically the issuance of debt/equity-linked securities. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it concerns a specific capital market transaction.
2021-04-28 English
DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028
Capital/Financing Update Classification · 98% confidence The document is a formal announcement from DiaSorin S.p.A. regarding its intention to issue €500 million in senior unsecured equity-linked bonds due 2028. This action directly relates to financing activities, specifically to partially fund the acquisition of Luminex Corporation. The text explicitly mentions the offering, the terms of the bonds, and the intended use of proceeds. This clearly falls under the definition of 'Capital/Financing Update' (CAP). Although it also mentions preliminary Q1 2021 results, the primary focus and headline subject is the bond offering, which is a capital/financing event. It is not a full 10-K, a standalone AR, or a simple ER/MRQ, but a specific capital market transaction announcement.
2021-04-28 English
DiaSorin annuncia l’avvio del collocamento di un prestito obbligazionario senior unsecured equity-linked per Euro 500 milioni con scadenza al 2028
Capital/Financing Update Classification · 98% confidence The document is a formal announcement from DiaSorin S.p.A. dated April 28, 2021. The subject line and headline explicitly state the announcement of the launch of a placement for a senior unsecured equity-linked bond issue of Euro 500 million. This clearly relates to a financing activity or capital structure change. The document also mentions preliminary consolidated results for Q1 2021 and a change in the 2021 financial calendar, but the primary, most significant action announced is the bond placement. This fits the definition of 'Capital/Financing Update' (CAP). It is not a full 10-K, an earnings release (ER) which is usually just highlights, or a general regulatory filing (RNS), as it describes a specific corporate finance action.
2021-04-28 Italian
DiaSorin - Shareholders' meeting April 22, 2021
AGM Information Classification · 98% confidence The document explicitly details the resolutions passed by the 'ORDINARY AND EXTRAORDINARY SHAREHOLDERS' MEETING OF DIASORIN S.P.A.' held on April 22, 2021. Key items approved include the financial statements, dividend distribution, remuneration policy, establishment of a stock option plan, authorization for treasury share transactions, and amendments to the By-Laws. This content directly relates to the formal proceedings and outcomes of an Annual General Meeting (AGM). Although it contains financial results (ER/IR content), the primary context and purpose of the communication is reporting the decisions made at the meeting itself. Therefore, the most appropriate classification is AGM-R (AGM Information).
2021-04-22 English
DiaSorin - Assemblea degli Azionisti 22 aprile 2021
AGM Information Classification · 98% confidence The document text explicitly mentions 'Assemblea degli Azionisti 2021' (Shareholders' Meeting 2021) and details the resolutions passed, such as the approval of the 2020 financial statements, dividend distribution, approval of a new Stock Option Plan, and amendments to the bylaws. The subject line in the metadata also confirms this: 'Oggetto: DiaSorin - Assemblea degli Azionisti 22 aprile 2021'. This content directly relates to the proceedings and outcomes of an Annual General Meeting (AGM). Although it contains financial results (which might suggest ER or IR), the primary context and purpose of the communication is reporting the decisions made at the AGM. Therefore, the most appropriate classification is AGM-R (AGM Information).
2021-04-22 Italian

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.